Melissa A Deri's research while affiliated with City University of New York City - Lehman College and other places

Publications (5)

Article
The ligand 3,4,3-LI(1,2-HOPO) or HOPO, which has four 1,2-hydroxypyridinone groups on a spermine backbone, has been shown to be an efficient and stable chelator for Zr(IV) and the bifunctional derivative, p-SCN-Bn-HOPO, can be conjugated to antibodies via the isothiocyanate group and radiolabeled with 89Zr at room temperature. The positron emission...
Article
Zirconium-89 has an ideal half-life for use in antibody-based PET imaging; however, when used with the chelator DFO, there is an accumulation of radioactivity in the bone, suggesting that the (89)Zr(4+) cation is being released in vivo. Therefore, a more robust chelator for (89)Zr could reduce the in vivo release and the dose to non-target tissues....
Article
Zirconium-89 is an effective radionuclide for antibody-based positron emission tomography (PET) imaging because its physical half-life (78.41 h) matches the biological half-life of IgG antibodies. Desferrioxamine (DFO) is currently the preferred chelator for (89)Zr(4+); however, accumulation of (89)Zr in the bones of mice suggests that (89)Zr(4+) i...
Article
The advent of antibody-based cancer therapeutics has led to the concomitant rise in the development of companion diagnostics for these therapies, particularly nuclear imaging agents. A number of radioisotopes have been employed for antibody-based PET and SPECT imaging, notably 64Cu, 124I, 111In, and 99mTc; in recent years, however, the field has in...

Citations

... The synthesis was carried out on the basis of the literature protocol with minor changes [20]. 6-Hydroxypicolinic acid (2.00 g, 14.38 mmol) was dissolved in acetic acid (8.2 mL) and neat TFA (12.2 mL). ...
... Additionally, a better version of the DFO chelator as DFO* has been developed to further strengthen the stability of 89 Zr complexation and has shown lower bone uptake over time 61 . Various other chelators are also being developed to address in vivo stability of the 89 Zr complex over time [62][63][64][65][66] . ...
... DFO* is structurally similar to DFO but offers an additional hyrdoxamate group, resulting in a total of 8 donor atoms and a more stable chelate (56). The HOPO chelator [3,4,3-(LI-1,2-HOPO)] offers the same amount of donor atoms and was reported to be an excellent alternative to DFO (57). Finally, we investigated DFOsqa, a deferoxamine conjugated to 3,4-diethoxy-3-cyclobutene-1,2-dione (squaric acid diethyl ester). ...
... One example is the radiolabelling of nivolumab with zirconium-89 ( 89 Zr), which showed the feasibility of such an approach in mapping PD-1 expression in humanized murine models of lung cancer [100]. Initial clinical evaluation of [ 89 Zr]Zr-DFO-nivolumab demonstrated its safety and ability to quantify PD-1 expression in patients with non-small cell lung carcinoma (NSCLC) [ 89 Zr-DFO chemistry makes it very attractive for labelling antibodies and smaller antibody fragments, such as minibodies [102]. Desferrioxamine B (DFO), as the name indicates, is originally an iron chelator derived from bacteria. ...